SCHEMBL4065251

SCHEMBL4065251

C[Si](C)(C)CCOCn1c(-c2ccc(-c3ccccc3)cc2)cnc1C=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
NPC1 O15118 1/20 0.36
DGAT1 O75907 5/20 0.35
KMT2A Q03164 3/20 0.33
MAPT P10636 2/20 0.33
F11 P03951 1/20 0.33
PORCN Q9H237 1/20 0.33
HPGDS O60760 1/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
ALOX15 P16050 2/20 0.32
MEN1 O00255 1/20 0.32
CYP2C9 P11712 1/20 0.32
PKM P14618 1/20 0.32
CYP2C19 P33261 1/20 0.32
FLT3 P36888 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4065268 0.88 TDP1 (0.44) TDP1ALDH1A1LMNADGAT1MAPT
SCHEMBL4068100 0.85 FYN (0.40) TDP1ALDH1A1MAPTKDM4E
SCHEMBL27596081 0.84 FYN (0.37) TDP1ALDH1A1LMNANPC1CYP1A2
SCHEMBL4064489 0.84 ALDH1A1 (0.38) ALDH1A1LMNANPC1KMT2AMAPT
SCHEMBL4064875 0.80 F11 (0.32) TDP1NPC1DGAT1MAPTF11
SCHEMBL4065179 0.78 EGFR (0.32) NPC1DGAT1FLT3
SCHEMBL27596318 0.78 DGAT1 (0.32) NPC1DGAT1FLT3
SCHEMBL6211362 0.77 NPC1 (0.35) NPC1DGAT1MAPTF11KDM4E
SCHEMBL25586533 0.77 DGAT1 (0.36) NPC1DGAT1MAPT
SCHEMBL9958624 0.77 NPC1 (0.33) NPC1DGAT1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317445-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2009-03-11 EP disclosed
US-7396840-B2 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION (US) 2008-07-08 US disclosed
US-7084155-B2 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2006-08-01 US disclosed
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2006-06-15 US disclosed
US-6864265-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2005-03-08 US disclosed
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-04 US disclosed
EP-1317445-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 EP disclosed
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2003-01-23 US disclosed
WO-2002022600-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 TDP1 4352/4885ALDH1A1 1755/4885LMNA 4836/4885
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds CXCR4, CCR5, CXCR3 TDP1 4221/4885ALDH1A1 2001/4885LMNA 4649/4885
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 TDP1 4352/4885ALDH1A1 1755/4885LMNA 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.